Related Experiment Videos
Schizophrenia: do we really need placebo-controlled studies?
J G Storosum1, A J Elferink, B J van Zwieten
1Medicines Evaluation Board of The Netherlands, Rijswijk.
Summary
Placebo control is essential for demonstrating treatment efficacy in short-term schizophrenia studies. Non-placebo-controlled trials may not adequately capture true treatment effects, especially regarding responder rates.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Short-term efficacy studies in schizophrenia often rely on placebo controls.
- The necessity of placebo control in these studies remains a subject of debate.
- Alternative control groups are being explored to assess treatment effectiveness.
Purpose of the Study:
- To evaluate the necessity of placebo control in short-term efficacy studies for schizophrenia.
- To compare efficacy outcomes between placebo-controlled and positive-controlled (non-placebo) studies.
- To determine if non-placebo-controlled studies adequately demonstrate treatment efficacy.
Main Methods:
- Comparative analysis of efficacy results from placebo-controlled versus positive-controlled studies.
- Focus on short-term treatment of chronic schizophrenia.
- Examination of both mean improvement scores (e.g., Brief Psychiatric Rating Scale - BPRS) and responder rates.
Main Results:
- Placebo arms in some studies showed worsening or minimal improvement on the BPRS.
- Mean improvement in haloperidol arms was comparable across placebo-controlled and non-placebo-controlled studies.
- Responder rates in non-placebo-controlled studies were often similar to placebo arms in placebo-controlled studies.
- Dropout rates were higher in placebo arms, particularly due to insufficient response in active treatment arms of non-placebo-controlled studies.
Conclusions:
- Placebo control is necessary to adequately demonstrate efficacy in short-term schizophrenia studies.
- Responder rates, a clinically relevant measure, showed significant variability in placebo arms, underscoring the need for placebo control.
- Current alternatives to placebo-controlled studies are insufficient for proving efficacy in schizophrenia patients, though consensus on responder definitions is needed.